Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Investors »
« Back

Aclaris - Investor Relations

Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts

Investor Contact

For investor related questions, please email

investors@aclaristx.com

Investor Overview

Stock quote

VOLUME:

View stock performance »

Minimum 15 minutes delayed. Source: LSEG

Investor Overview

Press Releases

December 3, 2024

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

November 26, 2024

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

November 18, 2024

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Events

Dec 3, 2024
1:00 PM EST

Piper Sandler 36th Annual Healthcare Conference

Nov 18, 2024
8:30 AM EST

Aclaris Corporate Update

Sep 17, 2024
8:00 AM EDT

2024 Cantor Global Healthcare Conference

Feature Presentation

Corporate Update Presentation

Corporate Overview Presentation

Aclaris - Footer Menu

Terms of Use
Privacy Policy
Contact Us
Fraudulent Activity Notice

© 2024 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.